AndreaBozzo/ceres-open-data-index huggingface dataset:
NNDSS - TABLE 1MM. Viral hemorrhagic fevers, Crimean-Congo hemorrhagic fever virus to Guanarito virus

NNDSS - TABLE 1MM. Viral hemorrhagic fevers, Crimean-Congo hemorrhagic fever virus to Guanarito virus - 2019. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. 

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published — CDC does not have data because of changes in how conditions are categorized.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
* Case counts for reporting years 2018 and 2019 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the US, a US territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-US Residents' category. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. 
† Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). 
§ Prior to 2015, CDC's National Notifiable Diseases Surveillance System (NNDSS) did not receive electronic data about incident cases of specific viral hemorrhagic fevers; instead data were collected in aggregate as "viral hemorrhagic fevers'. NNDSS was updated beginning in 2015 to receive data for each of the viral hemorrhagic fevers listed.
Program Instruction (PI-20-09)

This Program Instruction (PI) provides State, Territorial, and Tribal title IV-E agencies (hereafter, "title IV-E agencies") with the revised form and instructions approved by the U.S. Office of Management and Budget (OMB) for reporting quarterly financial information on the title IV-E Foster Care, Adoption Assistance, Guardianship Assistance, Kinship Navigator and Prevention Services Programs, as well as annual information relating to Adoption Savings.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 528880: Dopamine, N-acetyl-TFA

Chemical compound data from PubChem database. IUPAC Name: [4-(2-acetamidoethyl)-2-(2,2,2-trifluoroacetyl)oxyphenyl] 2,2,2-trifluoroacetate. Molecular Formula: C14H11F6NO5. Molecular Weight: 387.23. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Evaluation of amplified rDNA restriction analysis (ARDRA) for the identification of cultured mycobacteria in a diagnostic laboratory

Background
          The development of DNA amplification for the direct detection of M. tuberculosis from clinical samples has been a major goal of clinical microbiology during the last ten years. However, the limited sensitivity of most DNA amplification techniques restricts their use to smear positive samples. On the other hand, the development of automated liquid culture has increased the speed and sensitivity of cultivation of mycobacteria. We have opted to combine automated culture with rapid genotypic identification (ARDRA: amplified rDNA restriction analysis) for the detection resp. identification of all mycobacterial species at once, instead of attempting direct PCR based detection from clinical samples of M. tuberculosis only.
        
        
          Results
          During 1998–2000 a total of approx. 3500 clinical samples was screened for the presence of M. tuberculosis. Of the 151 culture positive samples, 61 were M. tuberculosis culture positive. Of the 30 smear positive samples, 26 were M. tuberculosis positive. All but three of these 151 mycobacterial isolates could be identified with ARDRA within on average 36 hours. The three isolates that could not be identified belonged to rare species not yet included in our ARDRA fingerprint library or were isolates with an aberrant pattern.
        
        
          Conclusions
          In our hands, automated culture in combination with ARDRA provides with accurate, practically applicable, wide range identification of mycobacterial species. The existing identification library covers most species, and can be easily updated when new species are studied or described. The drawback is that ARDRA is culture-dependent, since automated culture of M. tuberculosis takes on average 16.7 days (range 6 to 29 days). However, culture is needed after all to assess the antibiotic susceptibility of the strains.
Results from the 2013 National Survey on Drug Use and Health: Mental Health Findings

This report present results from the 2013 National Survey on Drug Use and Health (NSDUH) Mental Health Findings, including national estimates of the prevalence of past year mental disorders and past year mental health service utilization for youths aged 12 to 17 and adults aged 18 or older. Among adults, estimates presented include rates and numbers of persons with any mental illness (AMI), serious mental illness (SMI), suicidal thoughts and behavior, major depressive episode (MDE), treatment for depression (among adults with MDE), and mental health service utilization. Estimates for youths include MDE, treatment for depression (among youths with MDE), and mental health service utilization. Measures related to the co-occurrence of mental disorders with substance use or with substance use disorders also are presented for both adults and youths. The report focuses mainly on trends between 2012 and 2013. Results are also provided by age group, gender, race/ethnicity, education level, employment status, county type, poverty level, insurance status, overal health, and geographic area.
Compound 528309: Pyrazine, 2-(methylthio)-3-propyl-

Chemical compound data from PubChem database. IUPAC Name: 2-methylsulfanyl-3-propylpyrazine. Molecular Formula: C8H12N2S. Molecular Weight: 168.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400996-T1: [Translated] MILK CUP LINING AND MILK CUP

This invention refers to a teatcup liner and a teatcup. The liner (1) is mounted in a shell (2) of the teatcup and defines an inner space (3) for receiving a teat. The liner includes a primary component (12) forming a barrel. The primary component includes a peripheral portion (15), a primary connecting ring (16) and a lip (17) defining an opening (4). The secondary component includes a secondary peripheral portion (18) and a secondary connecting ring (20). The primary component is connectable to the secondary component for releasing the liner by a mutual engagement of the connecting rings. At least one of the connecting rings abuts the peripheral portion of the other component to form a sealing abutment between the two components.
Compound 528453: 1-Nonene, 4,8-dimethyl

Chemical compound data from PubChem database. IUPAC Name: 4,8-dimethylnon-1-ene. Molecular Formula: C11H22. Molecular Weight: 154.29. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Selumetinib

Koselugo (selumetinib) is a prescription oral medication manufactured by AstraZeneca Pharmaceuticals LP. It acts as a kinase inhibitor, targeting MEK1 and MEK2 enzymes. Available in capsule forms (10mg and 25mg) and granules (equivalent to 5mg and 7.5mg base), it's used to treat certain conditions like neurofibromatosis type 1 in children. This information was generated using AI and is provided for informational and research purposes only.
NNDSS - Table II. Meningococcal disease to Pertussis

NNDSS - Table II. Meningococcal disease to Pertussis - 2018. In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states or territory.

Note:

This table contains provisional cases of selected national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up.  Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html.
 
Footnotes:

C.N.M.I.: Commonwealth of Northern Mariana Islands. 
U: Unavailable. —: No reported cases. N: Not reportable. NA:  Not Available.  NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. 

* Case counts for reporting years 2017 and 2018 are provisional and subject to change. Data for years 2013 through 2016 are finalized. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf.
Tennessee: 2011-2012 NSDUH

This report presents Tennessee\'s estimates for 25 measures of substance use and mental health based on the combined 2011 and 2012 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided by State and for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Child Welfare Outcomes 2021: Report to Congress

This Report to Congress provides information on the performance of states on seven national outcome categories and also includes data on contextual factors and findings of analyses conducted across states.

Note: The PDF is best viewed in Chrome or Firefox. If using Internet Explorer (IE), please right click the link, save the file, and view it locally.

Appendix A: Adoption and Safe Families Act of 1997 (Pub. L. 105—89)

Appendix B: Child Welfare Outcomes Report: Outcomes and Measures

Appendix C: Caseworker Visits

Appendix D: Child Welfare Outcomes Report: Data Sources and Elements

Appendix E: Child Maltreatment 2020: Summary of Key Findings

Appendix F: The AFCARS Report 28: FY 2020 Estimates

Appendix G: Data-Quality Criteria

Metadata-only record linking to the original dataset. Open original dataset below.
Medicare COVID-19 Hospitalization Trends

The Medicare COVID-19 Hospitalization Trends dataset contains aggregate information from Medicare Fee-for-Service claims, Medicare Advantage encounter, and Medicare enrollment data. It provides insight around the groups of beneficiaries that were hospitalized at different points during the pandemic.

 

CMS publicly released the first Preliminary Medicare COVID-19 Snapshot in June 2020 during the early stages of the Public Health Emergency for COVID-19. That report focused on COVID-19 cases and hospitalizations data for Medicare beneficiaries with a COVID-19 diagnosis. Throughout 2020 and 2021, that report was subsequently updated with refreshed data 13 times. Beginning in October 2021, CMS shifted its public COVID-19 reporting away from cumulative case and hospitalization rates to hospitalization trends over time with the release of this report, the Medicare COVID-19 Hospitalization Trends Report. 

 

All prior releases of both the Preliminary Medicare COVID-19 Snapshot and the Medicare COVID-19 Hospitalization Trends Report are available for download in the Medicare COVID-19 Data - Prior Releases file.
MD COVID-19 - Total Probable Deaths Statewide

<b>Note:</b> Starting April 27, 2023 updates change from daily to weekly.

<b>Summary</b>
The cumulative number of probable COVID-19 deaths among Maryland residents.

<b>Description</b>
The MD COVID-19 - Total Probable Deaths Statewide data layer is a collection of the statewide probable COVID-19 related deaths that have been reported each day by the Vital Statistics Administration. A death is classified as probable if the person's death certificate notes COVID-19 to be a probable, suspect or presumed cause or condition. Probable deaths are not yet been confirmed by a laboratory test. Some data on deaths may be unavailable due to the time lag between the death, typically reported by a hospital or other facility, and the submission of the complete death certificate. Confirmed deaths are available from the MD COVID-19 - Total Confirmed Deaths Statewide data layer.

<b>Terms of Use</b>
The Spatial Data, and the information therein, (collectively the "Data") is provided "as is" without warranty of any kind, either expressed, implied, or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted, nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct, indirect, incidental, consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data, nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.
Treatment Episode Data Set (TEDS): 2019 Admissions to and Discharges from Publicly-Funded Substance Use Treatment

This report presents national- and state-level data from the Treatment Episode Data Set (TEDS) for admissions and discharges occurring in 2019, and trend data from 2009 to 2019. It summarizes demographic information and the characteristics and outcomes of treatment for alcohol and/or drug use among clients aged 12 years and older in facilities that report to individual state administrative data systems. Data include records for treatment admissions and discharges that were received and processed through November 3, 2020.
Supporting Evidence-Based Home Visitation Programs to Prevent Child Abuse and Neglect Project: The County of Solano Department of Health and Social Services

Location:

Fairfield, California

Home Visiting Program Selected:

Nurse Family Partnership

Home Visiting Target Population:

Low-income, first-time mothers in the County with significant risk factors for child maltreatment, along with pregnant transitional-age youth previously or currently involved in foster care or in relationships with former or current foster care youth.

Project Overview:
The County of Solano Department of Health and Social Services will work closely with community partners currently providing home visitation services, including BabyFirst Solano, a public-private partnership established in 2003 to make sure babies born in the County are healthy and able to thrive, to implement a Nurse Family Partnership (NFP) home visiting program. The Department expects to receive referrals to NFP from a diverse group of collaborative partner agencies and programs such as public health clinics, WIC clinics, family resource centers, and private physicians. To implement the grant, the Department's child welfare and public health divisions will collaborate with each other, including combining funding streams to support NFP. They will also work with mental health, substance abuse treatment, and employment and eligibility divisions. The grantee plans to compare outcomes, costs, and benefits of NFP with other, non-evidence-based home visiting models in the county, and will engage an external evaluator to conduct the evaluation.

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E400249-T1: [Translated] COSMETIC COMPOSITION CONTAINING AT LEAST ONE ANIONIC SURFACTANT, AT LEAST ONE CATIONIC POLYMER AND AT LEAST ONE BRANCHED AMPHIPHILIC ACRYLIC BLOCK COPOLYMER AND HAIR TREATMENT METHOD USING THIS COMPOSITION

Cosmetic composition comprises branched amphiphilic block copolymer(s) (I), cationic polymer(s) (II) and at least 3 wt.% of an anionic surfactant. (I) comprises 1-20C alkyl (meth)acrylate, N-(2-12C alkyl)-(meth)acrylamide or N,N-di(2-12C alkyl)-(meth)acrylamide units; (meth)acrylic acid units; and units derived from monomer(s) having at least two polymerizable unsaturated groups.  An Independent claim is also included for treatment of keratinic materials by applying the composition and then rinsing the keratinic materials.
Compound 526709: 4-Butyramidophenyl acetate

Chemical compound data from PubChem database. IUPAC Name: [4-(butanoylamino)phenyl] acetate. Molecular Formula: C12H15NO3. Molecular Weight: 221.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Research Article: BMC Gastroenterology

Background
          The 13C-urea breath test (UBT) is performed in adults and children with epigastric pain for non-invasively diagnosing a suspected H. pylori infection. Criteria for UBT interpretation have not been generally agreed on and test reliability has not been established in children of different ages. This study aimed at identifying reliable UBT thresholds in children by using 251 UBTs in conjunction with reference histology and by analyzing 1232 UBTs.
        
        
          Methods
          At baseline and 30 and 60 minutes after the administration of 75 mg 13C-urea to children and adolescents (0.25 to 18 years of age), the differences (Δ) of 13CO2/12CO2 ratio in exhaled air (δ) were determined by mass spectrometry. UBT Δδ value thresholds were calculated in random subgroups and evaluated in complementary subgroups using logistic regressions on reference histology or bimodal distribution analyses of Δδ values from UBTs alone.
        
        
          Results
          Δδ values were higher (median, 15.4‰) in positive (133/251, 53 %) than in negative histology (2.4‰). At 30 minutes, the calculated cut-off was 5.3‰ (mean regression determination R2 = 0.91), and sensitivity (0.95), specificity (0.97), positive (0.97) and negative predictive values (0.95) were higher than at 60 minutes (threshold 6.8‰, R2 = 0.85). Similar thresholds resulted from UBTs analysis (5.8‰ and 6.2‰) when sensitivity and specificity were maximized (concordance probabilities, 0.99 and 0.99). There was no systematic age effect.
        
        
          Conclusions
          In children, 13C UBT cut-offs were obtained and specially validated, entailing high accuracy of non-invasively testing for gastric H. pylori infection.
Compound 526943: 2-Thienyl 1-methyl-2-oxobutyl disulphide

Chemical compound data from PubChem database. IUPAC Name: 2-(thiophen-2-yldisulfanyl)pentan-3-one. Molecular Formula: C9H12OS3. Molecular Weight: 232.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Critical care medicine in the 21st century: from CPR to PCR

As in other areas of medicine, the specialty of critical care medicine, which has made important contributions in the pathophysiology of critical illness, is facing challenges that must be recognized and addressed in the current century. In this review, we argue that the skill set required to adequately treat critically ill patients will also require knowledge of molecular biology for better diagnosis and treatment. The foundations of molecular biology and genetics are essential for the understanding of the mechanisms of disease. Incorporating molecular biology techniques in the research arsenal of the intensivist will provide the opportunity to dissect out and define the reversible and irreversible intracellular processes giving rise to the major causes of mortality in intensive care units. Two historical paradigms, the cardiopulmonary resuscitation and polymerase chain reaction, summarize how critical care medicine began, and how it could mature in the years to come.
A missense mutation (Q279R) in the Fumarylacetoacetate Hydrolase gene, responsible for hereditary tyrosinemia, acts as a splicing mutation

Background
          Tyrosinemia type I, the most severe disease of the tyrosine catabolic pathway is caused by a deficiency in fumarylacetoacetate hydrolase (FAH). A patient showing few of the symptoms associated with the disease, was found to be a compound heterozygote for a splice mutation, IVS6-1g->t, and a putative missense mutation, Q279R. Analysis of FAH expression in liver sections obtained after resection for hepatocellular carcinoma revealed a mosaic pattern of expression. No FAH was found in tumor regions while a healthy region contained enzyme-expressing nodules.
        
        
          Results
          Analysis of DNA from a FAH expressing region showed that the expression of the protein was due to correction of the Q279R mutation. RT-PCR was used to assess if Q279R RNA was produced in the liver cells and in fibroblasts from the patient. Normal mRNA was found in the liver region where the mutation had reverted while splicing intermediates were found in non-expressing regions suggesting that the Q279R mutation acted as a splicing mutation in vivo. Sequence of transcripts showed skipping of exon 8 alone or together with exon 9. Using minigenes in transfection assays, the Q279R mutation was shown to induce skipping of exon 9 when placed in a constitutive splicing environment.
        
        
          Conclusion
          These data suggest that the putative missense mutation Q279R in the FAH gene acts as a splicing mutation in vivo. Moreover FAH expression can be partially restored in certain liver cells as a result of a reversion of the Q279R mutation and expansion of the corrected cells.